Abstract

Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137. sCD137 was functionally active and augmented T cell proliferation. Our findings shed new light on the regulation of CD137/CD137L immune responses with potential impact on immunotherapeutic approaches targeting CD137.

Highlights

  • IntroductionCD137 ( known as 4-1BB and TNFRSF9) is a type I transmembrane protein of the TNFR family that is widely expressed on cells of both the innate and adaptive immune system

  • CD137 is a type I transmembrane protein of the TNFR family that is widely expressed on cells of both the innate and adaptive immune system

  • The aim of this study was to examine whether human CD137 could be released by proteolytic shedding. We show that this is the case and identify ADAM10 as the major responsible proteinase, with ADAM17 assuming an additional potential role

Read more

Summary

Introduction

CD137 ( known as 4-1BB and TNFRSF9) is a type I transmembrane protein of the TNFR family that is widely expressed on cells of both the innate and adaptive immune system. It was originally discovered in screens for inducible genes in activated T cells [1,2]. Numerous studies devoted to its functional characterization on activated T cells and natural killer cells have been published implicating decisive potential of CD137 as a target for immunotherapies [3,4]. CD137L is co-expressed with its receptor on activated T-lymphocytes [8,9,10]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call